JP2023540444A5 - - Google Patents

Info

Publication number
JP2023540444A5
JP2023540444A5 JP2023507798A JP2023507798A JP2023540444A5 JP 2023540444 A5 JP2023540444 A5 JP 2023540444A5 JP 2023507798 A JP2023507798 A JP 2023507798A JP 2023507798 A JP2023507798 A JP 2023507798A JP 2023540444 A5 JP2023540444 A5 JP 2023540444A5
Authority
JP
Japan
Prior art keywords
antibody
seq
cdr
antigen
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023507798A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023540444A (ja
Filing date
Publication date
Priority claimed from GBGB2012331.1A external-priority patent/GB202012331D0/en
Application filed filed Critical
Publication of JP2023540444A publication Critical patent/JP2023540444A/ja
Publication of JP2023540444A5 publication Critical patent/JP2023540444A5/ja
Pending legal-status Critical Current

Links

JP2023507798A 2020-08-07 2021-08-06 治療用抗体 Pending JP2023540444A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2012331.1A GB202012331D0 (en) 2020-08-07 2020-08-07 Therapeutic antibodies
GB2012331.1 2020-08-07
PCT/GB2021/052043 WO2022029447A1 (en) 2020-08-07 2021-08-06 Therapeutic antibodies

Publications (2)

Publication Number Publication Date
JP2023540444A JP2023540444A (ja) 2023-09-25
JP2023540444A5 true JP2023540444A5 (enExample) 2026-02-02

Family

ID=72520053

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023507798A Pending JP2023540444A (ja) 2020-08-07 2021-08-06 治療用抗体

Country Status (8)

Country Link
US (1) US20230272097A1 (enExample)
EP (1) EP4192867A1 (enExample)
JP (1) JP2023540444A (enExample)
CN (1) CN116249710A (enExample)
AU (1) AU2021319941A1 (enExample)
CA (1) CA3186391A1 (enExample)
GB (1) GB202012331D0 (enExample)
WO (1) WO2022029447A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240052871A (ko) 2016-04-27 2024-04-23 애브비 인코포레이티드 항-il-13 항체를 이용한 il-13 활성이 유해한 질환의 치료 방법
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
US20220332837A1 (en) * 2021-04-08 2022-10-20 Colorado State University Research Foundation Methods and compositions for ox40 activation in treatment of canine cancer
IL314314A (en) * 2022-02-09 2024-09-01 Petmedix Ltd Therapeutic antibodies
GB202217978D0 (en) * 2022-11-30 2023-01-11 Petmedix Ltd Rodents expressing a common light chain
AU2023417626A1 (en) 2022-12-27 2025-07-10 Invetx, Inc. Polypeptides with altered binding to neonatal fc receptor (fcrn) and methods of use
WO2024155982A2 (en) 2023-01-20 2024-07-25 Invetx, Inc. Bispecific binding agents for use in companion animals
WO2025174998A1 (en) * 2024-02-13 2025-08-21 Invetx, Inc. Anti-il-31ra antibodies and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
AU2005229009A1 (en) * 2004-03-23 2005-10-13 Amgen, Inc. Monoclonal antibodies specific for human OX40L (CD 134L)
GB0525662D0 (en) 2005-12-16 2006-01-25 Glaxo Group Ltd Immunoglobulins
US7812133B2 (en) * 2005-12-16 2010-10-12 Genentech, Inc Anti-OX40L antibodies and methods using same
HRP20180858T1 (hr) 2011-07-11 2018-09-21 Glenmark Pharmaceuticals S.A. Protutijela koja se vežu na ox40 i njihove uporabe
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
AU2013221502C1 (en) * 2012-02-14 2018-03-01 Boehringer Ingelheim Animal Health USA Inc. Recombinant poxviral vectors expressing both rabies and OX40 proteins, and vaccines made therefrom
GB201316644D0 (en) 2013-09-19 2013-11-06 Kymab Ltd Expression vector production & High-Throughput cell screening
US10196435B2 (en) 2013-11-18 2019-02-05 University Of Southern California OX40L fusion protein for the immunotherapy of tumors of veterinary animals
KR102740384B1 (ko) 2015-03-03 2024-12-06 키맵 리미티드 항체, 용도 및 방법
GB2561352B (en) 2017-04-10 2023-01-18 Genome Res Ltd Animal models and therapeutic molecules
KR20250026872A (ko) 2018-03-16 2025-02-25 조에티스 서비시즈 엘엘씨 수의학적 용도를 위한 인터류킨-31 단클론성 항체
GB2578867A (en) 2018-10-09 2020-06-03 Genome Res Ltd Animal models and therapeutic molecules

Similar Documents

Publication Publication Date Title
US20250122301A1 (en) Cd25 antibodies
RU2474588C2 (ru) Перекрестно-реактивные антитела анти-il-17a/il-17f и способы их применения
Willems et al. Rituximab therapy for childhood-onset systemic lupus erythematosus
US10479830B2 (en) Anti eotaxin-2 antibodies that recognize additional CCR3-binding chemokines
HUE034282T2 (en) A monoclonal antibody to dog interleukin-31
RU2014121043A (ru) Биспецифические иммуносвязывающие средства, направленные против tnf и il-17
CN109384844B (zh) 一种抗金黄色葡萄球菌α溶血素单克隆抗体及应用
JP2017513813A5 (enExample)
WO2009140348A4 (en) Anti-il-6/il-6r antibodies and methods of use thereof
JP2023540444A (ja) 治療用抗体
JP2017525655A5 (enExample)
WO2022117079A1 (zh) 结合胸腺基质淋巴细胞生成素的抗体及其应用
JP2022527646A5 (enExample)
WO2005114218B1 (en) Cross-screening system and methods for detecting a molecule having binding affinity for a target molecule
JP2025506488A5 (enExample)
Hu et al. Potential therapeutic strategies in chronic inflammatory demyelinating polyradiculoneuropathy
RU2024121576A (ru) Терапевтические антитела
US20240360210A1 (en) Use of an il-18 antagonist for treating and/or prevention of atopic dermatitis or a related condition
KR20230154239A (ko) 항체-매개 이식 거부의 치료에 사용하기 위한 항-cd38 항체
CN118715244A (zh) 治疗性抗体
JP2025506488A (ja) 治療抗体
CN104391114B (zh) Elisa方法定量测定人血清中重组人鼠嵌合抗cd20单克隆抗体浓度
RU2795411C2 (ru) Моноклональные антитела к интерлейкину-31 для ветеринарного применения
HK40063825A (en) Cd25 antibodies
NZ773527B2 (en) Antibodies, uses & methods